Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,615.00
Bid: 1,614.00
Ask: 1,615.00
Change: 17.00 (1.06%)
Spread: 1.00 (0.062%)
Open: 1,595.00
High: 1,626.00
Low: 1,588.00
Prev. Close: 1,598.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Monday broker round-up UPDATE

Mon, 16th Jun 2014 09:51

Allocate Software: N+1 Singer upgrades to buy with a target price of 133p.Croda International: Numis cuts target price from 2575p to 2554p and maintains its hold recommendation.Diamondcorp: Northland Capital shifts target price from 9.9p to 11p and keeps a buy recommendation.Fenner: Credit Suisse reduces target price from 490p to 405p and stays with its outperform rating.GlaxoSmithKline: Societe Generale ups target price from 2075p to 2100p and retains a buy recommendation.Glencore Xstrata: Investec moves target price from 302p to 319p upgrading from reduce to hold.Halma: Credit Suisse ups target price from 620p to 665p and reiterates an outperform rating.IG Group: Canaccord Genuity cuts target price from 711p to 659p, while staying with its buy recommendation.Laird: Credit Suisse raises target price from 215p to 270p, while leaving its underperform rating unchanged.Lamprell: Investec shifts target price from 150p to 155p and reiterates a hold recommendation.Morgan Advanced Materials: Credit Suisse ups target price from 270p to 310p and maintains an underperform rating.Oxford Instruments: N+1 Singer ups target price to 1445p and maintains its hold recommendation.Petra Diamonds: Numis moves target price from 200p to 220p keeping its buy recommendation.Reckitt Benckiser: Exane raises target price from 4500p to 4900p, while staying with its underperform rating.Rio Tinto: Investec reduces target price from 3624p to 3128p downgrading from buy to hold. Exane reduces target price from 4070p to 3800p and stays with its outperform rating.Rolls-Royce Group: Societe Generale reduces target price from 1070p to 950p downgrading from hold to sell.Rotork: Credit Suisse increases target price from 2450p to 2600p and stays with its neutral rating.Senior: Credit Suisse moves target price from 315p to 335p and keeps an outperform rating.Science in Sport: Sanlam Securities initiates with a target price of 83p and a buy recommendation.Zambeef: Panmure Gordon reinstates with a target price of 30p and a buy recommendation.
More News
30 Oct 2023 09:01

IN BRIEF: GSK says Jemperli meets endpoint in endometrial cancer trial

GSK PLC - Brentford, west London-based pharmaceutical maker - Jemperli, whose generic name is dostarlimab, meets endpoint of overall survival in phase III Ruby trial on adult patients with primary advanced or recurrent endometrial cancer. Jemperli, combined with standard-of-care chemotherapy, followed by dostarlimab, demonstrated a "statistically significant and clinically meaningful benefit" to the patients in the trial.

Read more
30 Oct 2023 07:06

GSK's Jemperli sees success in endometrial cancer trial

(Sharecast News) - GSK reported encouraging outcomes from part one of the 'RUBY' phase three trial evaluating the efficacy of 'Jemperli', or dostarlimab, with standard chemotherapy for treating adult patients with advanced or recurrent endometrial cancer on Monday.

Read more
26 Oct 2023 09:19

TOP NEWS: GSK subsidiary ViiV receives HIV drug approval in China

(Alliance News) - GSK PLC on Thursday said its subsidiary ViiV Healthcare has received marketing authorisation in China for its cabotegravir treatment, marketed as Vocabria.

Read more
26 Oct 2023 07:02

GSK HIV injection regimen gets approval in China

(Sharecast News) - GSK announced on Thursday that its majority-owned HIV specialist subsidiary ViiV has received approval from the National Medical Products Administration (NMPA) of China for an injection regimen.

Read more
25 Oct 2023 16:01

UK earnings, trading statements calendar - next 7 days

Thursday 26 October 
Bank of Ireland Group PLCTrading Statement
Bloomsbury Publishing PLCHalf Year Results
Botswana Diamonds PLCTrading Statement
C&C Group PLCHalf Year Results
e-Therapeutics PLCHalf Year Results
Financials Acquisition CorpTrading Statement
GCP Infrastructure Investments LtdTrading Statement
HarbourVest Global Private Equity LtdHalf Year Results
Hummingbird Resources PLCTrading Statement
Hunting PLCTrading Statement
Inchcape PLCTrading Statement
International Personal Finance PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
Renishaw PLCTrading Statement
Standard Chartered PLCQ3 Results
Unilever PLCTrading Statement
WPP PLCTrading Statement
Friday 27 October 
International Consolidated Airlines Group SAQ3 Results
NatWest Group PLCQ3 Results
Monday 30 October 
Airtel Africa PLCHalf Year Results
Computacenter PLCTrading Statement
Glencore PLCTrading Statement
HSBC Holdings PLCQ3 Results
Lok'n Store Group PLCFull Year Results
Pearson PLCTrading Statement
Tuesday 31 October 
BP PLCQ3 Results
Coca-Cola HBC AGTrading Statement
Elementis PLCTrading Statement
essensys PLCFull Year Results
Georgia Capital PLCQ3 Results
Grit Real Estate Income Group LtdFull Year Results
RHI Magnesita NVTrading Statement
Spectris PLCQ3 Results
TP ICAP Group PLCTrading Statement
UP Global Sourcing Holdings PLCFull Year Results
Wednesday 1 November 
Asos PLCFull Year Results
Aston Martin Lagonda Global Holdings PLCQ3 Results
Beximco Pharmaceuticals LtdFull Year Results
GSK PLCQ3 Results
Next PLCTrading Statement
Smurfit Kappa Group PLCTrading Statement
Weir Group PLCTrading Statement
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
25 Oct 2023 09:35

GSK says RSV jab shows promising response in adults aged 50 to 59

(Alliance News) - GSK PLC on Wednesday said a trial found its respiratory syncytial virus vaccine Arexy delivered an immune response in adults aged 50 to 59.

Read more
25 Oct 2023 07:27

GSK hails success in US RSV vaccine trial

(Sharecast News) - Pharma giant GSK has announced positive preliminary results from a trial of its Arexvy vaccine to treatment respiratory syncytial virus (RSV) disease for a younger patient population in the US.

Read more
16 Oct 2023 08:09

TOP NEWS: GSK receives positive EU opinion on Jemperli for cancer

(Alliance News) - GSK PLC on Monday said its monoclonal antibody Jemperli is closer to becoming the first new frontline treatment option in the EU in decades for a certain form of endometrial cancer.

Read more
16 Oct 2023 07:44

LONDON BRIEFING: Hipgnosis pulls interim dividend on lower royalties

(Alliance News) - The FTSE 100 is likely to open higher on Monday, benefitting from higher oil and gas prices, while fears of escalating regional conflict in the Middle East damp risk sentiment elsewhere.

Read more
16 Oct 2023 07:16

GSK nears green light for Jemperli usage in Europe

(Sharecast News) - Pharma giant GSK has announced that European experts recommended the approval of its Jerperli drug for the treatment of a specific type of endometrial cancer - paving the way for marketing authorisation by the continent's regulatory body.

Read more
11 Oct 2023 11:51

GSK settles California Zantac lawsuit

(Sharecast News) - GSK has agreed to settle another lawsuit concerning its discontinued heartburn treatment Zantac, the drugs giant confirmed on Wednesday.

Read more
11 Oct 2023 09:17

LONDON BROKER RATINGS: JPMorgan raises Croda; Berenberg cuts Atalaya

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning:

Read more
11 Oct 2023 08:51

LONDON MARKET OPEN: FTSE 100 higher; Travis Perkins warns on profit

(Alliance News) - Stock prices in London opened largely higher on Wednesday as market mood remained resilient, despite the continuing conflict in the Middle East, amid a softening of rhetoric from the US central bank.

Read more
11 Oct 2023 08:36

TOP NEWS: GSK reaches settlement for Zantac litigation in California

(Alliance News) - GSK PLC on Wednesday said that it has reached a confidential settlement in the Cantlay/Harper case, which alleged that the firm's heartburn medication can cause cancer.

Read more
11 Oct 2023 07:47

LONDON BRIEFING: Stocks lower; GSK settles Zantac case in California

(Alliance News) - Stocks in London are set to open lower on Wednesday as investor looked ahead to the release of the US Federal Reserve's September meeting minutes later in the day.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.